Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property
Piyusha P. Pagare(Virginia Commonwealth University), Martin K. Safo(Virginia Commonwealth University), Andrew N. Fleischman, Abdelsattar M. Omar(Al-Azhar University), Yan Zhang, Osheiza Abdulmalik(Children's Hospital of Philadelphia), Aref Rastegar(Virginia Commonwealth University)
Cited by 22
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
|Science|2018|159
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression
|Journal of Clinical Investigation|2014|125